Outcomes of the patients with metastatic male breast cancer


Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.

Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.98-102, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 1
  • Publication Date: 2024
  • Doi Number: 10.4103/jcrt.jcrt_1829_22
  • Journal Name: Journal of Cancer Research and Therapeutics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.98-102
  • Keywords: Male breast cancer, metastases, prognosis
  • Istanbul University Affiliated: Yes

Abstract

Background: The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast cancer (mMBC). Methods: A retrospective analysis of the data of 28 patients was conducted. Kaplan–Meier and Cox regression analyses were used to assess overall survival (OS) and prognostic variables. Results: At the time of diagnosis, the median age was 57 years (range 26–86). The most prevalent pathological subtype was invasive ductal carcinoma (92.6%). HER2 positivity was 21.6% in patients, with estrogen and progesterone receptor positivity at 96.4% and 71.4%, respectively. Bone-75%, lung-39.3%, brain-21.4%, and adrenal gland-10.7% were the most prevalent metastatic sites. Trastuzumab-based chemotherapy was given to six patients. During the study period, 14 patients (or half) died. All patients had a median OS of 42.6 months (range: 21.6–63.7). The OS rates after 1, 3, and 5 years were 95.7%, 54.2%, and 36.6%, respectively. The number of metastatic locations (P = 0.045), brain metastasis (P = 0.033), and a history of regular alcohol intake (P = 0.008) were all shown to be statistically significant factors affecting OS in univariate analysis. However, multivariate analysis did not support the findings. In addition, we discovered that trastuzumab-based therapy and de-novo metastatic disease had no effect on OS for mMBC. Conclusions: The data on mMBC is restricted because of its rarity. The prognosis of mMBC was shown to be poor in this investigation. Despite the small number of patients, we discovered that in univariate analysis, having brain metastases, the number of metastatic locations, and a history of alcohol intake may be prognostic factors.